drugset
drugset / Trial / NCT02702427

Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation

NCT02702427 ↗

Phase 1/2 Withdrawn St. Anna Children's Cancer Research
NaSingle-groupOpen-labelTreatment

Summary

Invasive infections with CMV and Adenovirus, not responding to virostatic treatment are treated with virusspecific donor derived or autologous virusspecific T-cells.

Timeline

Start
2016-08-03
Primary completion
2019-04-01
Completion
2019-04-01

Outcome

Outcome not reported

Stopped (Enrollment): “unsuccessful recruitment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Virus specific T cells Cell therapy — —

Indications

adenoviridae infectious disease cytomegalovirus infection